Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mona A. Abdullaziz"'
Autor:
Talea Knak, Mona A. Abdullaziz, Stefan Höfmann, Leandro A. Alves Avelar, Saskia Klein, Matthew Martin, Markus Fischer, Nobutada Tanaka, Thomas Kurz
Publikováno v:
Pharmaceuticals, Vol 15, Iss 12, p 1553 (2022)
To address the continued rise of multi-drug-resistant microorganisms, the development of novel drugs with new modes of action is urgently required. While humans biosynthesize the essential isoprenoid precursors isopentenyl diphosphate (IPP) and dimet
Externí odkaz:
https://doaj.org/article/6b337041a5eb46fba37c191faecc4642
Autor:
Heba T. Abdel-Mohsen, Mona A. Abdullaziz, Ahmed M. El Kerdawy, Fatma A. F. Ragab, Keith J. Flanagan, Abeer E. E. Mahmoud, Mamdouh M. Ali, Hoda I. El Diwani, Mathias O. Senge
Publikováno v:
Molecules, Vol 25, Iss 4, p 770 (2020)
In this study, a novel series of 1,2-disubstituted benzo[d]imidazoles was rationally designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. Our design strategy is two-fold; it aimed first at studying the effect of replacing the 5-methylfu
Externí odkaz:
https://doaj.org/article/d5681756020243118eccfbe786f07279
Autor:
Hoda I. El Diwani, Mona A. Abdullaziz, Abeer E. Mahmoud, Mathias O. Senge, Keith J. Flanagan, Fatma A.F. Ragab, Heba T. Abdel-Mohsen, Mamdouh M. Ali, Ahmed M. El Kerdawy
Publikováno v:
Molecules
Molecules, Vol 25, Iss 4, p 770 (2020)
Volume 25
Issue 4
Molecules, Vol 25, Iss 4, p 770 (2020)
Volume 25
Issue 4
In this study, a novel series of 1,2-disubstituted benzo[d]imidazoles was rationally designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. Our design strategy is two-fold
it aimed first at studying the effect of replacing the 5-meth
it aimed first at studying the effect of replacing the 5-meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95ae0c9ce896e8271acfd93cb698b63
https://doi.org/10.3390/molecules25040770
https://doi.org/10.3390/molecules25040770
Autor:
Fatma A.F. Ragab, Hoda I. El Diwani, Mamdouh M. Ali, Sherifa M. Abu-bakr, Mona A. Abdullaziz, Heba T. Abdel-Mohsen, Adel S. Girgis, Ahmed M. El Kerdawy
Publikováno v:
European journal of medicinal chemistry. 136
Inhibition of angiogenesis through inhibition of vascular endothelial growth factor receptor 2 (VEGFR-2) has been applied in cancer therapy because of its important role in promoting cancer growth and metastasis. In the presented study, a series of b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22b66c97a610e2b72ec484f71acdbea6
https://pubmed.ncbi.nlm.nih.gov/28505536
https://pubmed.ncbi.nlm.nih.gov/28505536